Meticulous Research® reports that the Veterinary Vaccines Market is forecast to grow at a 6.1% CAGR from 2024, reaching $11.13 billion by 2030. Key factors fueling this growth include an increasing number of livestock animals, rising pet adoption rates, and the spread of animal diseases. There is also significant demand for animal-derived food products, which supports vaccine use in livestock to maintain health standards. However, market expansion is restricted by the high costs of manufacturing and storage for vaccines. On the other hand, rising awareness about animal health and increased spending on animal healthcare present growth opportunities for companies in this field, although low awareness about animal health in certain regions remains a notable challenge.
Market Segmentation and Future Prospects
The veterinary vaccines market is segmented by vaccine type, type of animal, route of administration, distribution channel, and region. By type, the market includes live attenuated, inactivated, and recombinant vaccines, among others. In 2024, live attenuated vaccines are anticipated to hold the largest market share due to their ability to trigger strong immune responses, providing animals with long-lasting protection against pathogens.
Download Sample Report : https://www.meticulousresearch.com/download-sample-report/cp_id=5618
By animal type, the market is divided into livestock and companion animals. The livestock segment is expected to grow at a faster rate as the demand for animal-based food increases. In developing countries, livestock population growth and government-backed programs to control animal diseases further fuel this segment. For instance, the Government of India launched the Animal Pandemic Preparedness Initiatives in 2024, which aims to improve disease surveillance, response, and vaccine research to safeguard animal health.
Regarding administration route, the veterinary vaccines market is segmented into parenteral, oral, and intranasal vaccines. Parenteral vaccines, which are administered through injection, are expected to be widely adopted due to their effectiveness and the ease of achieving high vaccine absorption rates.
The distribution channel analysis highlights veterinary hospitals and clinics as the dominant segment in 2024. This can be attributed to pet owners’ preference for professional settings for animal vaccination, especially since vaccines must be administered by licensed veterinarians. Hospitals and clinics are preferred due to their convenience and the broad range of services they offer, solidifying their position as the leading distribution channel for veterinary vaccines.
Regional Overview
The veterinary vaccines market spans several key regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is projected to be the largest market in 2024, supported by a large base of livestock and pets, high awareness of animal health, and a strong focus on animal health management practices. This region’s leadership is also bolstered by established animal healthcare infrastructure, high adoption of vaccines, and the significant production of animal-derived food. Europe and Asia-Pacific are also expected to capture substantial shares, as awareness of animal health increases and government initiatives promote disease prevention.
Customize My Report : https://www.meticulousresearch.com/request-customization/cp_id=5618
In conclusion, the global veterinary vaccines market is poised for consistent growth driven by rising demand for livestock and pet health solutions. Although challenges related to cost and awareness exist, the market shows strong potential with advancements in vaccine technology and supportive government initiatives.
Key Market Players
Major players in the veterinary vaccines market include Zoetis Inc. (U.S.), Virbac (France), Ceva Santé Animale (France), Boehringer Ingelheim International GmbH (Germany), Phibro Animal Health Corporation (U.S.), Merck & Co., Inc. (U.S.), Elanco Animal Health Inc. (U.S.), Vetoquinol (France), Neogen Corporation (U.S.), and Indian Immunologicals Ltd. (India).
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
